News & insights

Search all news & insights

    Latest news

    Show
    news from

    OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025

    Beacon Therapeutics completes enrolment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

    Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

    OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025

    Northern Gritstone invests in Manchester spinout Apini

    Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

    View all news

    Latest insights & articles

    Show
    insights & articles from

    Introducing Slingshot Therapeutics

    Creating Yellowstone – Syncona’s launch team in action

    A spotlight on our female leaders

    Introducing iOnctura

    Challenges continue but brighter days on the horizon

    Navigating the biotech landscape: A journey from big pharma to innovative startups

    View all insights & articles

    Latest publications & presentations

    Show presentations from

    Spur Corporate Presentation - February 2025

    Download PDF (2.75Mb)

    Autolus Corporate Presentation - January 2025

    Download PDF (2.38Mb)

    Syncona - Half Year 2024 Presentation

    Download PDF (3.42Mb)

    Syncona Investor Webinar: Beacon Therapeutics

    Download PDF (1.64Mb)

    Spur Corporate Presentation - October 2024

    Download PDF (1.81Mb)

    Autolus Corporate Presentation - September 2024

    Download PDF (1.71Mb)
    View all publications & presentations

    Search